/PRNewswire/ Citrine Medicine, a China-based rare disease therapeutics company, today announced that it has signed a licensing agreement with Diurnal Group.
REPUBLIC OF SOUTH AFRICA OR
JAPAN. NEITHER THIS ANNOUNCEMENT NOR ANYTHING CONTAINED HEREIN SHALL FORM THE BASIS OF, OR BE RELIED UPON IN CONNECTION WITH, ANY OFFER OR COMMITMENT WHATSOEVER IN ANY JURISDICTION.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU AS IT FORMS PART OF THE LAW OF
ENGLAND AND
WALES BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. IN ADDITION, MARKET SOUNDINGS WERE TAKEN IN RESPECT OF THE MATTERS CONTAINED IN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF SUCH INSIDE INFORMATION. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION.
Citrine Medicine and Sinopharm Group Announce Strategic Partnership to Broaden and Accelerate Access to Rare Disease Drugs in China
Collaboration to focus on establishing supply chain and securing distribution channels for delivering rare disease therapies to patients across China
News provided by
Share this article
Share this article
BOSTON and SHANGHAI, April 19, 2021 /PRNewswire/ Citrine Medicine, a China-based rare disease therapeutics company, and Sinopharm Group, a Chinese pharmaceutical company, today announced a strategic partnership to accelerate the commercialization of rare disease drugs in China. The two companies will work together to build a rare disease ecosystem in China and enable the availability of more rare disease therapies to Chinese patients in need.
Citrine Medicine To Present at the 2021 WuXi Healthcare Forum and Participate in Two Additional Upcoming Healthcare Conferences
News provided by
Share this article
Share this article
CAMBRIDGE, Mass. and SHANGHAI, March 16, 2021 /PRNewswire/ Citrine Medicine, a China-based rare disease therapeutics company, today announced that it will participate in three industry conferences in March, including a presentation at the 2021 WuXi Healthcare Forum, which will be held from March 15-18, 2021.
Conference details are as follows:
WuXi Healthcare Forum: Citrine s management will participate in the CEO Roundtable on March 16 from 6:15-6:45 p.m. PT, and on March 17 from 6:45-7:15 p.m. PT. The discussion will be accessible live and interactively via a dedicated portal for registered attendees.
Feb 05 2021 Read 2500 Times
Pharmaceutical companies Diurnal Group and Citrine Medicine (China) have established a licencing agreement for Diurnal’s Alkindi® (hydrocortisone granules in capsules for opening) covering China, Hong Kong, Taiwan and Macau.
Under the terms of the licence agreement Cardiff-based Diurnal, targeting patient needs in chronic endocrine (hormonal) conditions, receives an upfront payment of $0.5 million and $12.75m in additional cash payments arising from certain regulatory and sales milestones, as well as tiered royalties on sales ranging from low to mid double-digits.
Citrine, co-founded by Vivo Capital, F-Prime Capital and Eight Roads Ventures, is focused on creating a therapeutic platform to deliver rare disease drugs to the Chinese market and to develop the first ever rare disease ecosystem in the country.